



GENFIT PRESENTS GFT505 RESULTS AT THE AMERICAN DIABETES ASSOCIATION'S 70th SCIENTIFIC SESSIONS

Lille (France), Cambridge (Massachusetts, United States), June 21, 2010 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces its schedule of poster presentations and activities at the American Diabetes Association's 70th Scientific Sessions in Orlando, Florida, on June 25-29, 2010.

One poster will present the safety and efficacy of GENFIT's lead-drug candidate, GFT505, in a double-blind, placebo-controlled Phase 2a trial. Another late-breaking poster will present how GFT505 simultaneously improves lipid and glucose homeostasis. GFT505 is a drug candidate for treatment of type 2 diabetes and prevention in patients with elevated fasting glucose and impaired glucose tolerance. Both posters will be presented during the poster session scheduled for 12:00 p.m. to 2:00 p.m. EDT on Monday, June 28.

GENFIT will also be hosting a media gathering located at the Regus HQ, Orlando, Florida, on Sunday, June 27, from 6:00 p.m. to 7:00 p.m. EDT. The gathering will feature three well-renowned experts who will present their thoughts and views focused around prediabetes and diabetes as a multifactorial disorder and diabetes related liver disorders along with the application of GFT505 in addressing the unmet needs in this area.

- Luc Van Gaal, M.D., from the Department of Endocrinology, Diabetology and Metabolism and Faculty of Medicine at the University of Antwerp, Antwerp University Hospital, Belgium;
- Kenneth Cusi, M.D., from the Division of Diabetes and Department of Medicine at the University of Texas Health Science Center, San Antonio, Texas; and
- Bart Staels, Ph.D., from University Lille Nord de France and Pasteur Institute of Lille, co-founder of GENFIT and chairman of its Scientific Advisory Board.

"The ADA's Scientific Sessions is an important annual event that will allow GENFIT to continue building relationships and we are proud to have the opportunity to present recent clinical data from our lead-drug candidate program, GFT505, at this key meeting," said Jean-François Mouney, chairman of GENFIT's Management Board.

GENFIT's 70th Scientific Sessions Schedule and Activities At-A-Glance

Sunday, June 27, 2010

- GENFIT Media Gathering: Clinical Data Demonstrating the Therapeutic Potential of GFT505 for the Management of Prediabetes and Associated Cardiometabolic Risk Factors
Place: Regus HQ, 7380 Sand Lake Road, Suite 500, Orlando, FL 32819
Time: 6:00 p.m. to 7:00 p.m. EDT
Further Details: GENFIT will be providing transportation to the media gathering for all of those attending. Food and refreshments will be available.

Monday, June 28, 2010

- Poster presentation: “GFT505 Efficacy and Safety in Healthy Volunteers and Patients Suffering from Atherogenic Dyslipidemia”
Presenting Author: Dr. Dean W. Hum, Ph.D.
Time: 12:00 p.m. to 2:00 p.m. EDT
Abstract #: 3034ADA10D1
Publication # 677-P
Room: Poster Hall
Location: Hall C, Orange County Convention Center
- Poster presentation: “GFT505 Improves Glucose and Lipid Homeostasis in Patients with Impaired Fasting Glucose and Impaired Glucose Tolerance”
Presenting Author: Dr. Rémy Hanf, Ph.D.
Time: 12:00 p.m. to 2:00 p.m. EDT
Abstract #: 536ADA10D1LB
Publication # 12-LB
Room: Poster Hall
Location: Hall C, Orange County Convention Center

About the American Diabetes Association’s 70th Scientific Sessions:

The ADA’s 70th Scientific Sessions is the world’s most prominent diabetes meeting. The meeting will be held in Orlando, Florida, on June 25-29, at the Orange County Convention Center in the West Building. This meeting provides the most recent education and information for those who are involved in the diabetes community.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in strategic therapeutic fields linked to cardiometabolic and neurodegenerative disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, Alzheimer’s...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health concerns and their unmet medical needs. GENFIT’s proprietary research programs and its partnerships with leading pharmaceutical companies, including SANOFI-AVENTIS, SOLVAY GROUP, and SERVIER, have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development. GENFIT’s lead proprietary compound, GFT505, is currently in Phase II and two other compounds, in partnership with SANOFI-AVENTIS and SOLVAY, are in the advanced stages of Phase I.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 120 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – Chairman of the Management Board
+33 (0)3 2016 4000

MILESTONES – Press Relations

Bruno Arabian
+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 – barabian@milestones.fr

MEDIA CONTACTS: RUSSO PARTNERS, LLC, ON BEHALF OF GENFIT

Chantal Beaudry
Phone: (212) 845-4272 - chantal.beaudry@russopartnersllc.com